3,4-Dihydroxybutanoic acid gamma-lactone, also known as gamma-butyrolactone, is a cyclic ester that is naturally occurring in various plants and animal tissues. It is a colorless, odorless liquid that is miscible with water and most organic solvents. It has been shown to have a variety of biological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. The compound is also used as a solvent and as an intermediate in the synthesis of other chemicals. Synthesis of 3,4-dihydroxybutanoic acid gamma-lactone can be achieved through various methods, including the reduction of maleic anhydride or the oxidation of tetrahydrofuran. The compound's biological activities have led to its investigation as a potential therapeutic agent for various conditions, including cancer, Alzheimer's disease, and Parkinson's disease. Research into the compound's potential medical applications is ongoing.'
```
3-hydroxy-gamma-butyrolactone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 95652 |
| SCHEMBL ID | 52211 |
| MeSH ID | M0158195 |
| Synonym |
|---|
| 4-hydroxydihydro-2(3h)-furanone |
| 5469-16-9 |
| nsc26907 |
| nsc-26907 |
| 4-hydroxyoxolan-2-one |
| 4-hydroxydihydrofuran-2(3h)-one , |
| A830323 |
| AKOS006228170 |
| 3,4-dihydroxybutyric acid gamma-lactone |
| ai3-05623 |
| 3,4-dihydroxybutanoic acid gamma-lactone |
| unii-0m94o5fn60 |
| 2(3h)-furanone, dihydro-4-hydroxy- |
| 0m94o5fn60 , |
| nsc 26907 |
| FT-0640502 |
| FT-0635748 |
| FT-0605326 |
| (+/-)-3-hydroxy-gamma-butyrolactone |
| SCHEMBL52211 |
| beta-hydroxy-gamma-butyrolactone |
| 3-hydroxy-gamma-butyrolactone |
| 4-hydroxy-dihydrofuran-2(3h)-one |
| 4-hydroxydihydrofuran-2-one |
| dihydro-4-hydroxy-2-(3h)-furanone |
| 4-hydroxydihydro-2(3h)-furanone # |
| 3-hydroxybutyrolactone |
| 3,4-dihydroxybutyric acid .gamma.-lactone |
| 3,4-dihydroxybutyric acid 1,4-lactone |
| butyric acid, .beta.,.gamma.-dihydroxy-, .gamma.-lactone |
| dihydro-4-hydroxy-2(3h)-furanone |
| 3-hydroxy-.gamma.-butyrolactone |
| mfcd00090014 |
| (+/-)-beta-hydroxy-gamma-butyrolactone |
| beta-hydroxybutyrolactone |
| DTXSID00872986 |
| AS-60546 |
| SY002401 |
| s-beta-hydroxy-gamma-butyrolactone |
| SB38494 |
| (s)-(-)-3-hydroxy-g-butyrolactone |
| Q27236966 |
| SB45411 |
| SY109494 |
| SY109477 |
| 131432-37-6 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (18.18) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.91) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (18.18%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (81.82%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||